VERTAVIS Drug Patent Profile
✉ Email this page to a colleague
When do Vertavis patents expire, and when can generic versions of Vertavis launch?
Vertavis is a drug marketed by Medpointe Pharm Hlc and is included in one NDA.
The generic ingredient in VERTAVIS is veratrum viride root. There are two drug master file entries for this compound. Additional details are available on the veratrum viride root profile page.
Summary for VERTAVIS
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | VERTAVIS at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for VERTAVIS
US Patents and Regulatory Information for VERTAVIS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medpointe Pharm Hlc | VERTAVIS | veratrum viride root | TABLET;ORAL | 005691-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
